Pair page
Cerebrolysin with Methylene Blue
Mechanism-tag overlap and published literature for Cerebrolysin and Methylene Blue, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
neurotrophic-brain-bioregulator
phenothiazine-dye-mitochondrial-electron-carrier
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying Cerebrolysin and Methylene Blue have published these mechanism-level observations. Not a co-administration recommendation.
Methylene blue's mitochondrial mechanism and tau-aggregation inhibition layer onto cerebrolysin's neurotrophic-factor mimicry at a mechanistic level. Combined for aggressive neuroprotective protocols, particularly in cognitive-decline concerns. No direct clinical trial.
Quick facts
Cerebrolysin
Methylene Blue
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2021 | Cerebrolysin | Vester JC, Buzoianu AD, Florian SI, Hömberg V, Kim SH, Lee TMC, Matula C, Poon WS, von Steinbüchel N, Strilciuc S, von Wild K, Muresanu D. Cerebrolysin after moderate to severe traumatic brain injury: prospective meta-analysis of the CAPTAIN trial series. Neurol Sci. 2021;42(2):… PMID 33620612 | meta-analysis |
| 2018 | Cerebrolysin | Bornstein NM, Guekht A, Vester J, Heiss WD, Gusev E, Hömberg V, Rahlfs VW, Bajenaru O, Popescu BO, Muresanu D. Safety and efficacy of Cerebrolysin in early post-stroke recovery: a meta-analysis of nine randomized clinical trials. Neurol Sci. 2018;39(4):629-640. PMID: 29248999. PMID 29248999 | meta-analysis |
| 2015 | Cerebrolysin | Gauthier S, Proaño JV, Jia J, Froelich L, Vester JC, Doppler E. Cerebrolysin in mild-to-moderate Alzheimer's disease: a meta-analysis of randomized controlled clinical trials. Dement Geriatr Cogn Disord. 2015;39(5-6):332-347. PMID: 25832905. PMID 25832905 | meta-analysis |
| 2020 | Cerebrolysin | Poon W, Vos P, Muresanu D, Vester J, von Wild K, Hömberg V, et al. Safety and efficacy of Cerebrolysin in acute brain injury and neurorecovery: CAPTAIN I — a randomized, placebo-controlled, double-blind, Asian-Pacific trial. Neurol Sci. 2020;41(2):281-293. PMID: 31494820. PMID 31494820 | human trial |
| 2020 | Cerebrolysin | Woo PYM, Ho JWK, Ko NMW, Li RPT, Jian L, Chu ACH, Kwan MCL, Chan Y, Wong AKS, Wong HT, Chan KY, Kwok JCK. Randomized, placebo-controlled, double-blind, pilot trial to investigate safety and efficacy of Cerebrolysin in patients with aneurysmal subarachnoid hemorrhage. BMC Neurol.… PMID 33143640 | human trial |
| 2017 | Cerebrolysin | Gharagozli K, Harandi AA, Houshmand S, Akbari N, Muresanu DF, Vester J, Winter S, Moessler H. Efficacy and safety of Cerebrolysin treatment in early recovery after acute ischemic stroke: a randomized, placebo-controlled, double-blinded, multicenter clinical trial. J Med Life. 20… PMID 29075343 | human trial |
| 2016 | Cerebrolysin | Muresanu DF, Heiss WD, Hoemberg V, Bajenaru O, Popescu CD, Vester JC, Rahlfs VW, Doppler E, Meier D, Moessler H, Guekht A. Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial. Stroke. 2016;47(1):151-159. PMID: 26564102. PMID 26564102 | human trial |
| 2016 | Cerebrolysin | Hassanein SM, Deifalla SM, El-Houssinie M, Mokbel SA. Safety and Efficacy of Cerebrolysin in Infants with Communication Defects due to Severe Perinatal Brain Insult: A Randomized Controlled Clinical Trial. J Clin Neurol. 2016;12(1):79-84. PMID: 26365023. PMID 26365023 | human trial |
| 2012 | Cerebrolysin | Heiss WD, Brainin M, Bornstein NM, Tuomilehto J, Hong Z; Cerebrolysin Acute Stroke Treatment in Asia (CASTA) Investigators. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke. 2012;43(3):630-636. PM… PMID 22282884 | human trial |
| 2010 | Cerebrolysin | Heiss WD, Brainin M, Bornstein NM, Tuomilehto J, Hong Z. A double-blind, placebo-controlled, randomized trial to evaluate the safety and efficacy of Cerebrolysin in patients with acute ischaemic stroke in Asia — CASTA. Int J Stroke. 2010;5(4):310-313. PMID: 19765131. PMID 19765131 | human trial |
| 2005 | Cerebrolysin | Ladurner G, Kalvach P, Moessler H; Cerebrolysin Study Group. Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial. J Neural Transm (Vienna). 2005;112(3):415-428. PMID: 15583955. PMID 15583955 | human trial |
| 2023 | Cerebrolysin | Rejdak K, Sienkiewicz-Jarosz H, Bienkowski P, Alvarez A. Modulation of neurotrophic factors in the treatment of dementia, stroke and TBI: Effects of Cerebrolysin. Med Res Rev. 2023;43(5):1668-1700. PMID: 37052231. PMID 37052231 | human study |
| 2016 | Methylene Blue | Gauthier S, Feldman HH, Schneider LS, Wilcock GK, Frisoni GB, Hardlund JH, Moebius HJ, Bentham P, Kook KA, Wischik DJ, Schelter BO, Davis CS, Staff RT, Bracoud L, Shamsi K, Storey JM, Harrington CR, Wischik CM. Efficacy and safety of tau-aggregation inhibitor therapy in patients… PMID 26806555 | human trial, Phase 3 |
| 2016 | Methylene Blue | Rodriguez P, Zhou W, Barrett DW, Altmeyer W, Gutierrez JE, Li J, Lancaster JL, Gonzalez-Lima F, Duong TQ. Multimodal randomized functional MR imaging of the effects of methylene blue in the human brain. Radiology. 2016;281(2):516-526. PMID: 27351678. DOI: 10.1148/radiol.20161528… PMID 27351678 | human trial |
| 2010 | Methylene Blue | Feldman HH, Doody RS, Kivipelto M, Sparks DL, Waters DD, Jones RW, Schwam E, Schindler R, Hey-Hadavi J, DeMicco DA, Breazna A; LEADe Investigators. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology. 2010;74(12):956-964. PMID: 202… PMID 20200346 | human trial |
| 2004 | Methylene Blue | Callaway NL, Riha PD, Bruchey AK, Munshi Z, Gonzalez-Lima F. Methylene blue improves brain oxidative metabolism and memory retention in rats. Pharmacol Biochem Behav. 2004;77(1):175-181. PMID: 14724055. PMID 14724055 | preclinical, in vivo |
| 2000 | Methylene Blue | Peter C, Hongwan D, Küpfer A, Lauterburg BH. Pharmacokinetics and organ distribution of intravenous and oral methylene blue. Eur J Clin Pharmacol. 2000;56(3):247-250. PMID: 10952480. PMID 10952480 | pharmacology |
| 2000 | Methylene Blue | Pelgrims J, De Vos F, Van den Brande J, Schrijvers D, Prové A, Vermorken JB. Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature. Br J Cancer. 2000;82(2):291-294. PMID: 10646879. PMID 10646879 | review |
| 2016 | Methylene Blue | FDA. ProvayBlue (methylene blue) prescribing information. NDA 204630. Approved April 8, 2016. Provepharm. | regulatory / registry |
| 2018 | Methylene Blue | Gauthier S, Feldman HH, Schneider LS, Wilcock GK, Wischik CM. Rember® and LMTM in Alzheimer's disease. Lancet Neurol. 2018;17(9):735-736. PMID: 30271090. PMID 30271090 | research article |
| 2012 | Methylene Blue | Rojas JC, Bruchey AK, Gonzalez-Lima F. Neurometabolic mechanisms for memory enhancement and neuroprotection of methylene blue. Prog Neurobiol. 2012;96(1):32-45. PMID: 22067440. DOI: 10.1016/j.pneurobio.2011.10.007. PMID 22067440 | research article |
| 2011 | Methylene Blue | Oz M, Lorke DE, Hasan M, Petroianu GA. Cellular and molecular actions of methylene blue in the nervous system. Med Res Rev. 2011;31(1):93-117. PMID: 19760660. PMID 19760660 | research article |
| 2011 | Methylene Blue | Schirmer RH, Adler H, Pickhardt M, Mandelkow E. Lest we forget you — methylene blue... Neurobiol Aging. 2011;32(12):2325.e7-2325.e16. PMID: 21316815. PMID 21316815 | research article |
| 2008 | Methylene Blue | Atamna H, Nguyen A, Schultz C, Boyle K, Newberry J, Kato H, Ames BN. Methylene blue delays cellular senescence and enhances key mitochondrial biochemical pathways. FASEB J. 2008;22(3):703-712. PMID: 17942826. DOI: 10.1096/fj.07-9610com. PMID 17942826 | research article |
Related pair pages
More research context
Frequently asked
Have Cerebrolysin and Methylene Blue been studied together?
Researchers have published mechanistic-level co-administration discussion of Cerebrolysin and Methylene Blue. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do Cerebrolysin and Methylene Blue share?
Cerebrolysin and Methylene Blue do not share a specific mechanism tag on their Kalios profiles. They appear on the same pair page because at least one profile lists the other in its co-administration data.
What is the FDA status of Cerebrolysin and Methylene Blue?
Cerebrolysin: Not approved (US). Methylene Blue: Approved (methemoglobinemia). FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on Cerebrolysin and Methylene Blue?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the Cerebrolysin profile and the Methylene Blue profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026